RICHARD LAWRENCE SIMMONS, MD
Radiology at 5 Ave, Pittsburgh, PA

License number

Pennsylvania MD039772E

Personal information

See more information about RICHARD LAWRENCE SIMMONS at radaris.com

Name

Address

Phone

Richard Simmons, age 77

515 New Bloomfield Rd, Duncannon, PA 17020

(717) 877-8139

Richard Simmons, age 40

503 S Filbert St, Mechanicsburg, PA 17055

(717) 420-7394

Richard Simmons

62 Knowlton Rd, Wellsboro, PA 16901

(570) 724-7596

Richard L Simmons

2103 Leishman Ave, New Kensington, PA 15068

(724) 334-2295

Richard L Simmons

3550 Terrace St, Pittsburgh, PA 15213

(412) 648-1823

Professional information

See more information about RICHARD LAWRENCE SIMMONS at trustoria.com

Dr. Richard L Simmons, Pittsburgh PA - MD (Doctor of Medicine)

Specialties:

General Surgery

Address:

497 Scaife Hall, Pittsburgh 15261
3601 5Th Ave, Pittsburgh 15213
(412) 647-3094 (Phone)
3550 Terrace St, Pittsburgh 15213
(412) 647-0680 (Phone), (412) 648-9551 (Fax)

Certifications:

General Surgery, 1989

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Boston University School of Medicine
Graduated: 1959
New York-Presbyterian Hospital
Harvard U
Massachusetts General Hospital

Hematopoietic Facilitatory Cells And Their Uses

US Patent:

5772994, Jun 30, 1998

Filed:

Jun 5, 1995

Appl. No.:

8/463908

Inventors:

Suzanne T. Ildstad - Pittsburgh PA
Richard L. Simmons - Pittsburgh PA
Camillo Ricordi - Miami Beach FL
Sherry M. Wren - Pittsburgh PA
Christina Kaufman - Munhall PA

Assignee:

The University of Pittsburgh - Pittsburgh PA

International Classification:

A01N 6300, C12N 1500

US Classification:

424 937

Abstract:

The present invention relates to mammalian hematopoietic facilitatory cells (FC). In particular, it relates to the isolation, characterization and uses of the FC. The FC of the present invention can be distinguished from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. It has now been established that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient. When co-administered with other bone marrow cells, especially the hematopoietic stem cells into a recipient, the FC enhance their engraftment, without apparent adverse biologic activities. In fact, the ability of the FC to enhance the engraftment of bone marrow cells in esablishing lymphohematopoietic chimerism without producing graft versus host disease also induces donor-specific tolerance to permit the permanent acceptance of donor's cells, tissues and organs. Therefore, FC may have a wide range of applications, including, but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.

Inducible Nitric Oxide Synthase For Treatment Of Disease

US Patent:

2002006, May 23, 2002

Filed:

Nov 13, 2001

Appl. No.:

09/992056

Inventors:

Timothy Billiar - Nevillewood PA, US
Edith Tzeng - Pittsburgh PA, US
David Geller - Pittsburgh PA, US
Richard Simmons - Pittsburgh PA, US
Larry Shears - Bethel Park PA, US
Andreas Nussler - Ulm, DE

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K048/00, A61K009/127, C12N015/861

US Classification:

514/044000, 435/320100, 424/450000, 435/456000

Abstract:

The invention provides a pharmaceutical composition comprising as an active ingredient a pharmaceutical agent comprising a DNA sequence that codes for a protein which possesses the biological activity of inducible nitrogen monoxide synthase (iNOS) and eukaryotic regulation elements, wherein the eukaryotic regulation elements result in the expression of said DNA sequence in eukaryotic cells, and a pharmaceutically acceptable carrier. The pharmaceutical agent can be complexed to liposomes.

Inducible Nitric Oxide Synthase Gene For Treatment Of Disease

US Patent:

5658565, Aug 19, 1997

Filed:

Jun 24, 1994

Appl. No.:

8/265046

Inventors:

Timothy R. Billiar - Pittsburgh PA
Edith Tzeng - Pittsburgh PA
Andreas K. Nussler - Neu-Ulm, DE
David A. Geller - Pittsburgh PA
Richard L. Simmons - Pittsburgh PA

Assignee:

University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 4800

US Classification:

424 9321

Abstract:

The present invention discloses a full-length human hepatocyte iNOS cDNA clone and various gene therapy applications utilizing an iNOS DNA sequence. In preferred embodiments of the disclosed invention, iNOS-directed gene therapy involves specific targeting of a DNA sequence encoding a protein or protein fragment with iNOS biological activity for treating vascular diseases and disorders, antitumor applications and in response to certain microbial infections.

Cdna Clone For Human Inducible Nitric Oxide Synthase And Process For Preparing Same

US Patent:

5468630, Nov 21, 1995

Filed:

Sep 28, 1994

Appl. No.:

8/314917

Inventors:

Timothy R. Billiar - Pittsburgh PA
Andreas K. Nussler - Pittsburgh PA
David A. Geller - Pittsburgh PA
Richard L. Simmons - Pittsburgh PA

Assignee:

University of Pittsburg of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12N 902, C12N 1553, C12N 1570, C12N 1579

US Classification:

435189

Abstract:

A human tissue inducible nitric oxide synthase cDNA clone is disclosed. A process for preparing this cDNA clone coding for human tissue inducible nitric oxide synthase and for expressing the human tissue inducible nitric oxide synthase protein are provided.